

CYP26A1 Antibody (C-term) Blocking Peptide
Synthetic peptide
Catalog # BP2754d**Specification**

CYP26A1 Antibody (C-term) Blocking Peptide - Product Information

Primary Accession [O43174](#)
Other Accession [Q5VXI0](#)

CYP26A1 Antibody (C-term) Blocking Peptide - Additional Information

Gene ID 1592

Other Names

Cytochrome P450 26A1, 114--, Cytochrome P450 retinoic acid-inactivating 1, Cytochrome P450RAI, hP450RAI, Retinoic acid 4-hydroxylase, Retinoic acid-metabolizing cytochrome, CYP26A1, CYP26, P450RAI1

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

CYP26A1 Antibody (C-term) Blocking Peptide - Protein Information

Name CYP26A1 {ECO:0000303|PubMed:26937021, ECO:0000312|HGNC:HGNC:2603}

Function

A cytochrome P450 monooxygenase involved in the metabolism of retinoates (RAs), the active metabolites of vitamin A, and critical signaling molecules in animals (PubMed:22020119, PubMed:9228017, PubMed:9716180). RAs exist as at least four different isomers: all- trans-RA (atRA), 9-cis-RA, 13-cis-RA, and 9,13-dicis-RA, where atRA is considered to be the biologically active isomer, although 9-cis-RA and 13-cis-RA also have activity (Probable). Catalyzes the hydroxylation of atRA primarily at C-4 and C-18, thereby contributing to the regulation of atRA homeostasis and signaling (PubMed:22020119, PubMed:9228017, PubMed:9716180). Hydroxylation of atRA limits its biological activity and initiates a degradative process leading to its eventual elimination (Probable). Involved in the conversion of atRA to all-trans-4-oxo-RA. Able to metabolize other RAs such as 9-cis, 13-cis and 9,13-di-cis RA (By similarity) (PubMed:<a

[9228017](http://www.uniprot.org/citations/9228017)). Can oxidize all-trans-13,14- dihydroretinoate (DRA) to metabolites which could include all-trans-4- oxo-DRA, all-trans-4-hydroxy-DRA, all-trans-5,8-epoxy-DRA, and all- trans-18-hydroxy-DRA (By similarity). May play a role in the oxidative metabolism of xenobiotics such as tazarotenic acid (PubMed:[26937021](http://www.uniprot.org/citations/26937021)).

Cellular Location

Endoplasmic reticulum membrane; Peripheral membrane protein. Microsome membrane; Peripheral membrane protein

Tissue Location

Expressed in most fetal and adult tissues with highest levels in adult liver, heart, pituitary gland, adrenal gland, placenta and regions of the brain (PubMed:9826557). Expressed at high levels in lung, pancreas, skin and uterus (at protein level) (PubMed:22020119). Lower expression level is detected in spleen, kidney, intestine and adipose tissue (at protein level) (PubMed:22020119).

CYP26A1 Antibody (C-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

CYP26A1 Antibody (C-term) Blocking Peptide - Images**CYP26A1 Antibody (C-term) Blocking Peptide - Background**

CYP26A1 is a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This endoplasmic reticulum protein acts on retinoids, including all-trans-retinoic acid (RA), with both 4-hydroxylation and 18-hydroxylation activities. This enzyme regulates the cellular level of retinoic acid which is involved in regulation of gene expression in both embryonic and adult tissues.

CYP26A1 Antibody (C-term) Blocking Peptide - References

Quere, R., Blood 109 (10), 4450-4460 (2007) Lee, S.J., Pharmacogenet. Genomics 17 (3), 169-180 (2007) Heise, R., J. Invest. Dermatol. 126 (11), 2473-2480 (2006)